144 related articles for article (PubMed ID: 25263078)
41. The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement.
Jackson AE; Smeltzer JP; Habermann TM; Jones JM; Burnette B; Ristow K; Wiseman GA; Macon WR; Nowakowski GS; Witzig TE
Am J Hematol; 2014 Sep; 89(9):865-7. PubMed ID: 24823914
[TBL] [Abstract][Full Text] [Related]
42. Value of 18F-FDG PET versus iliac biopsy in the initial evaluation of bone marrow infiltration in the case of Hodgkin's disease: a meta-analysis.
Cheng G; Alavi A
Nucl Med Commun; 2013 Jan; 34(1):25-31. PubMed ID: 23111383
[TBL] [Abstract][Full Text] [Related]
43. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography with gallium-67 scintigraphy in the initial clinical staging of diffuse large B-cell lymphoma.
Sakurai M; Toyama T; Kikuchi T; Kato J; Shimizu T; Koda Y; Karigane D; Yamane Y; Abe R; Yamazaki R; Nakazato T; Nakahara T; Jinzaki M; Okamoto S; Mori T
Int J Hematol; 2018 Feb; 107(2):194-200. PubMed ID: 28994017
[TBL] [Abstract][Full Text] [Related]
44. Bone marrow infiltration by flow cytometry at diffuse large B-cell lymphoma NOS diagnosis implies worse prognosis without considering bone marrow histology.
Martín-Moro F; Piris-Villaespesa M; Marquet-Palomanes J; García-Cosío M; Villarrubia J; Lario A; García I; Michael B; Roldán E; García-Vela JA; Lopez-Jiménez J
Cytometry B Clin Cytom; 2020 Nov; 98(6):525-528. PubMed ID: 31873987
[TBL] [Abstract][Full Text] [Related]
45. PET/CT versus bone marrow biopsy in the initial evaluation of bone marrow infiltration in various pediatric malignancies.
Zapata CP; Cuglievan B; Zapata CM; Olavarrieta R; Raskin S; Desai K; De Angulo G
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28901637
[TBL] [Abstract][Full Text] [Related]
46. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma.
Cerci JJ; Györke T; Fanti S; Paez D; Meneghetti JC; Redondo F; Celli M; Auewarakul C; Rangarajan V; Gujral S; Gorospe C; Campo MV; Chung JK; Morris TP; Dondi M; Carr R;
J Nucl Med; 2014 Oct; 55(10):1591-7. PubMed ID: 25214642
[TBL] [Abstract][Full Text] [Related]
47. Bone marrow uptake of indolent non-Hodgkin lymphoma on PET/CT with histopathological correlation.
Lee EY; Gill H; Wang Y; Kwong YL; Khong PL
Nucl Med Commun; 2015 Oct; 36(10):1035-41. PubMed ID: 26225940
[TBL] [Abstract][Full Text] [Related]
48. Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.
Wolach O; Fraser A; Luchiansky M; Shapiro C; Radnay J; Shpilberg O; Lishner M; Lahav M
Hematol Oncol; 2015 Mar; 33(1):42-7. PubMed ID: 24470400
[TBL] [Abstract][Full Text] [Related]
49. Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy.
Ribrag V; Vanel D; Leboulleux S; Lumbroso J; Couanet D; Bonniaud G; Aupérin A; Masson F; Bosq J; Edeline V; Fermé C; Pigneur F; Schlumberger M
Eur J Radiol; 2008 May; 66(2):325-31. PubMed ID: 17651934
[TBL] [Abstract][Full Text] [Related]
50. Routine bone marrow biopsy in the initial evaluation of primary cutaneous B-cell lymphoma does not appear justified.
Quereux G; Frot AS; Brocard A; Leux C; Renaut JJ; Dreno B
Eur J Dermatol; 2009; 19(3):216-20. PubMed ID: 19251565
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic and Prognostic Value of Using 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Peripheral T-Cell Lymphoma.
Abe Y; Kitadate A; Usui Y; Narita K; Kobayashi H; Miura D; Takeuchi M; Oʼuchi E; Oʼuchi T; Matsue K
Clin Nucl Med; 2019 May; 44(5):e336-e341. PubMed ID: 30889000
[TBL] [Abstract][Full Text] [Related]
52. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma].
Wen JJ; Liu ZB; Xu J; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791
[TBL] [Abstract][Full Text] [Related]
53. Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI).
Talaulikar D; Shadbolt B; Dahlstrom JE; McDonald A
J Hematol Oncol; 2009 Nov; 2():49. PubMed ID: 19930611
[TBL] [Abstract][Full Text] [Related]
54. [Evaluation of the enhanced International Prognostic Index (NCCN-IPI) for cases with diffuse large B-cell lymphoma].
Yamada A; Tamura H; Asayama T; Moriya K; Okuyama N; Kondo-Onodera A; Hamada Y; Ishibashi M; Yokose N; Tanosaki S; Inokuchi K
Rinsho Ketsueki; 2015 Jul; 56(7):915-8. PubMed ID: 26256931
[TBL] [Abstract][Full Text] [Related]
55. [Analysis of prognostic risk factors in patients with diffuse large B-cell lymphoma].
Yu ZP; Ding JH; Chen BA; Gao C; Wang LL; Chen Z
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):830-5. PubMed ID: 22339956
[TBL] [Abstract][Full Text] [Related]
56. Staging DLBCL: bone marrow biopsy or PET-CT?
Avigdor A
Blood; 2013 Jul; 122(1):4-5. PubMed ID: 23828884
[TBL] [Abstract][Full Text] [Related]
57. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
58. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin.
Melchardt T; Troppan K; Weiss L; Hufnagl C; Neureiter D; Tränkenschuh W; Hopfinger G; Magnes T; Deutsch A; Neumeister P; Hackl H; Greil R; Pichler M; Egle A
Br J Haematol; 2015 Jan; 168(2):239-45. PubMed ID: 25236324
[TBL] [Abstract][Full Text] [Related]
59. A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score.
Yhim HY; Park Y; Han YH; Kim S; Kang SR; Moon JH; Jeong JH; Shin HJ; Kim K; Choi YS; Kim K; Kim MK; Kong E; Kim DS; Eo JS; Lee JH; Kang DY; Lee WS; Lee SM; Do YR; Ham JS; Kim SJ; Kim WS; Choi JY; Yang DH; Kwak JY
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2274-2284. PubMed ID: 30056546
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
